Home » Fibromyalgia is a disabling disease, the approval comes from the Chamber

Fibromyalgia is a disabling disease, the approval comes from the Chamber

by admin
Fibromyalgia is a disabling disease, the approval comes from the Chamber

The Government has recently made a significant step in the world of healthcare by recognizing fibromyalgia syndrome as a chronic and disabling condition. In a landmark decision, six motions were approved unanimously, leading to fibromyalgia being included in the essential levels of assistance (Lea). This means that patients suffering from fibromyalgia will now be exempt from spending on healthcare services, providing much-needed relief for those affected by this often debilitating condition.

But what exactly is fibromyalgia? This chronic rheumatic disease is characterized by widespread muscle pain that is not linked to any inflammation. Other symptoms include difficulty concentrating, memory deficits, sleep disorders, fatigue, muscle stiffness, and sensitivity to pressure. While there is no definitive cure or known cause for fibromyalgia, treatment typically involves the use of analgesics, muscle relaxants, and antidepressants.

Medical hypotheses suggest that fibromyalgia may be linked to a variety of genetic and environmental factors, specifically involving an impairment of the central nervous system. The brain’s ability to process painful stimuli may be compromised in those with fibromyalgia, leading to the constant and generalized pain experienced by patients.

The recognition of fibromyalgia as a chronic and disabling condition by the Government is a significant victory for those affected by this syndrome. With the inclusion of fibromyalgia in the essential levels of assistance, patients can now access the necessary healthcare services without the burden of additional costs. This decision marks a positive step forward in the treatment and support of individuals living with fibromyalgia.

See also  Hair removal techniques: better razor, wax, electric epilator, cream or laser?

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy